Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target
As of March 13, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) carried a Moderate Buy consensus on Wall Street.
Ionis Pharmaceuticals Inc (IONS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 3,052,111 | $241,452,501 | +48% | 0.47% |
| 2. | Citadel Investment Group Ken Griffin | 2,134,636 | $168,871,054 | -12% | 0.03% |
| 3. | Deerfield Management James E. Flynn | 1,979,669 | $156,611,615 | 2% | |
| 4. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,791,841 | $141,752,542 | +217% | 0.83% |
| 5. | Deep Track Capital David Kroin | 1,700,000 | $134,487,000 | -56% | 2.4% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.86 | 15,000 | $477,900.00 | 50,219 | 2025-05-01 | Filing | |
| $36.23 | 2,500 | $90,583.00 | 35,219 | 2024-12-23 | Filing | |
| $36.20 | 2,500 | $90,495.75 | 32,719 | 2024-12-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.21 | 10,172 | $744,661.60 | 82,660 | 2026-03-17 | Filing | |
| $72.77 | 9,440 | $686,901.60 | 92,832 | 2026-03-16 | Filing | |
| $72.38 | 205,608 | $14,882,112.65 | 102,272 | 2026-03-16 | Filing | |
| $80.00 | 200 | $16,000.00 | 36,330 | 2026-03-04 | Filing | |
| $80.33 | 832 | $66,832.81 | 36,330 | 2026-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 24,072,101 | $1,904,343,910 | 0.1% | |
| 2. | 17,961,299 | $1,420,918,364 | 0.19% | |
| 3. | 16,440,459 | $1,300,604,712 | 0.02% | |
| 4. | 10,647,863 | $842,352,443 | 0.01% | |
| 5. | AmundiBOND | 3,200,000 | $508,256,000 | 0.14% |
News See All
11 Best Growth Stocks to Invest in According to Billionaires
Infotech and biotech remain two of the clearer growth pockets because the underlying spending data is still expanding.
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best strong buy healthcare stocks to invest in. Ionis Pharmaceuticals, Inc.
11 Best Strong Buy Healthcare Stocks to Invest In
On February 23, Steven Wieting, CIO Group chief investment strategist, appeared on CNBC’s ‘The Exchange’ to talk about the stock market and the recent price action in stocks.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2025 Earnings Call Transcript February 25, 2026Ionis Pharmaceuticals, Inc. misses on earnings expectations.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the Ionis Pharmaceuticals, Inc. Third Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis (IONS) Price Target Hiked Following Positive Zilganersen Trial Results
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) ranks among the best biotech stocks to buy. On September 24, Leerink Partners maintained its Outperform rating on Ionis Pharmaceuticals, Inc.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
Ionis Pharma (IONS) Hits New High Anew as Analyst Sees Blockbuster Potential for Olezarsen
Ionis Pharmaceuticals extended its winning streak to a third straight day on Wednesday to touch a new all-time high, following an investment firm’s bullish rating and higher price target for its stock...
Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results
Ionis Pharmaceuticals soared to a new all-time high on Tuesday, as investors cheered promising results from the phase 3 studies of its drug candidate for the treatment of severe hypertriglyceridemia (...
Hedge Fund Resource Center